The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling.

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

An unnecessary FDA policy is making it nearly impossible for schizophrenics without stable medical care to get clozapine, the only medicine useful for treatment-resistant schizophrenia. In the absence ...

The FDA approved clozapine, which is classified as an “atypical” antipsychotic drug, for treatment-resistant schizophrenia in 1990. In 2002, the FDA announced clozapine was effective in reducing the ...

The FDA approved clozapine, which is classified as an “atypical” antipsychotic drug, for treatment-resistant schizophrenia in 1990. In 2002, the FDA announced clozapine was effective in ...